Risk for Birth Defects Not Increased With Adalimumab

Risk for Birth Defects Not Increased With Adalimumab News Professional Risk for Birth Defects Not Increased With Adalimumab Print Share All NewsConsumerProNew DrugsPipelineClinical TrialsFDA AlertsMore Risk for Birth Defects Not Increased With Adal

FDA Approves Vumerity FDA Approves Vumerity (diroximel fumarate) for Multiple Sclerosis

FDA Approves Vumerity FDA Approves Vumerity (diroximel fumarate) for Multiple Sclerosis CAMBRIDGE, Mass. and DUBLIN, Ireland, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Fo

Health Tip: Advice for Better Looking Hair

Health Tip: Advice for Better Looking Hair -- Maintaining smooth, shiny hair doesnt have to be difficult. The products and techniques you use to wash your hair can go a long way, says the American Academy of Dermatology. The academy suggests you: W

Most Widely Prescribed Blood Pressure Medicines Might Not Be Best Option: Study

Kids Trampoline Injuries Take Another Bounce Upwards

Kids Trampoline Injuries Take Another Bounce Upwards FRIDAY, Oct. 25, 2019 -- Trampolines arent just for backyards anymore, and the rise in commercial trampoline parks may be sparking a rise in kids injuries, a new report finds. "While trampolines are

FDA Approves Biorphen FDA Approves Biorphen (phenylephrine hydrochloride) Ready-to-Use Injection for Hypotension During Anesthesia

FDA Approves Biorphen FDA Approves Biorphen (phenylephrine hydrochloride) Ready-to-Use Injection for Hypotension During Anesthesia DEER PARK, Ill., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical